Wohlfahrtiimonas chitiniclastica: current insights into an emerging human pathogen

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • P Schröttner - , Institute of Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus (Author)
  • W W Rudolph - , Institute of Medical Microbiology and Virology (Author)
  • U Damme - , University Hospital Carl Gustav Carus Dresden (Author)
  • C Lotz - , University Hospital Carl Gustav Carus Dresden (Author)
  • E Jacobs - , Institute of Medical Microbiology and Virology (Author)
  • F Gunzer - , Institute of Medical Microbiology and Virology (Author)

Abstract

Since the first description of Wohlfahrtiimonas chitiniclastica in 2008, a number of well described case reports demonstrating its pathogenic role in humans have been published. Infections may be closely linked to flies, such as Wohlfahrtia magnifica, Lucilia sericata, Chrysomya megacephala or Musca domestica. These insects are potent vectors for the distribution of W. chitiniclastica causing local or systemic infections originating from wounds infested with fly larvae. However, other potential sources of transmission of W. chitiniclastica have been described such as soil or chicken meat. Infections in humans reported to date comprise wound infections, cellulitis, osteomyelitis and sepsis. This review summarizes all the literature available up to now and gives the current knowledge about this emerging human pathogen. Additionally, four patients with proven W. chitiniclastica infections treated at Dresden University Hospital between 2013 and 2015, are included. Special focus was placed on microbiological identification and antibiotic susceptibility testing of the pathogen.

Details

Original languageEnglish
Pages (from-to)1292-1303
Number of pages12
JournalEpidemiology and infection
Volume145
Issue number7
Publication statusPublished - May 2017
Peer-reviewedYes

External IDs

PubMedCentral PMC9203347
Scopus 85011632779

Keywords

Keywords

  • Animals, Anti-Bacterial Agents/pharmacology, Gammaproteobacteria/drug effects, Germany, Gram-Negative Bacterial Infections/drug therapy, Humans, Microbial Sensitivity Tests